# C_2015306EN.01002401.xml

| 17.9.2015 | EN | Official Journal of the European Union | C 306/24 |
| --- | --- | --- | --- |

17.9.2015

EN

Official Journal of the European Union

C 306/24

---

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2014

(2015/C 306/09)

Subcommittee I on the free movement of goods

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 July–31 December 2014, at their meeting on 20 March 2015:

| Annex I | List of new marketing authorisations |
| --- | --- |
| Annex II | List of renewed marketing authorisations |
| Annex III | List of extended marketing authorisations |
| Annex IV | List of withdrawn marketing authorisations |
| Annex V | List of suspended marketing authorisations |

Annex I

Annex I

List of new marketing authorisations

Annex II

Annex II

List of renewed marketing authorisations

Annex III

Annex III

List of extended marketing authorisations

Annex IV

Annex IV

List of withdrawn marketing authorisations

Annex V

Annex V

List of suspended marketing authorisations

---

ANNEX I

List of new marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 July – 31 December 2014:

| EU Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/09/527 | Ribavirin Teva Pharma BV | Liechtenstein | 31.12.2014 |
| EU/1/09/585 | Rivastigmine 1A Pharma | Liechtenstein | 31.10.2014 |
| EU/1/09/591 | Multaq | Liechtenstein | 31.10.2014 |
| EU/1/09/595 | Sildenafil Actavis | Liechtenstein | 31.10.2014 |
| EU/1/09/598 | Nevirapine Teva | Liechtenstein | 31.8.2014 |
| EU/1/09/599 | Rivastigmine Sandoz | Liechtenstein | 31.8.2014 |
| EU/1/09/600 | Zutectra | Liechtenstein | 31.10.2014 |
| EU/1/11/688 | Cinryze | Liechtenstein | 31.12.2014 |
| EU/1/11/705 | Vibativ | Iceland | 27.10.2014 |
| EU/1/12/772 | Zoledronsäure Teva Pharma | Liechtenstein | 31.12.2014 |
| EU/1/13/902 | Translarna | Iceland | 15.8.2014 |
| EU/1/13/902 | Translarna | Liechtenstein | 31.8.2014 |
| EU/1/13/902 | Translarna | Norway | 12.8.2014 |
| EU/1/14/917 | Ulunar Breezhaler | Iceland | 22.7.2014 |
| EU/1/14/931 | Mekinist | Iceland | 21.7.2014 |
| EU/1/14/931 | Mekinist | Liechtenstein | 31.8.2014 |
| EU/1/14/931 | Mekinist | Norway | 14.7.2014 |
| EU/1/14/933 | Simbrinza | Liechtenstein | 31.8.2014 |
| EU/1/14/933 | Simbrinza | Norway | 7.8.2014 |
| EU/1/14/933 | Simbrinza | Iceland | 14.8.2014 |
| EU/1/14/934 | Plegridy | Iceland | 15.8.2014 |
| EU/1/14/934 | Plegridy | Liechtenstein | 31.8.2014 |
| EU/1/14/934 | Plegridy | Norway | 13.8.2014 |
| EU/1/14/935 | Envarsus | Iceland | 14.8.2014 |
| EU/1/14/935 | Envarsus | Liechtenstein | 31.8.2014 |
| EU/1/14/935 | Envarsus | Norway | 13.8.2014 |
| EU/1/14/936 | Nuwiq | Iceland | 10.10.2014 |
| EU/1/14/936 | Nuwiq | Norway | 18.8.2014 |
| EU/1/14/937 | Gazyvaro | Iceland | 14.8.2014 |
| EU/1/14/937 | Gazyvaro | Liechtenstein | 31.8.2014 |
| EU/1/14/937 | Gazyvaro | Norway | 13.8.2014 |
| EU/1/14/938 | Zydelig | Iceland | 25.9.2014 |
| EU/1/14/938 | Zydelig | Liechtenstein | 31.10.2014 |
| EU/1/14/938 | Zydelig | Norway | 2.10.2014 |
| EU/1/14/939 | Daklinza | Iceland | 11.9.2014 |
| EU/1/14/939 | Daklinza | Liechtenstein | 31.8.2014 |
| EU/1/14/939 | Daklinza | Norway | 9.9.2014 |
| EU/1/14/940 | Triumeq | Iceland | 12.9.2014 |
| EU/1/14/940 | Triumeq | Liechtenstein | 31.10.2014 |
| EU/1/14/940 | Triumeq | Norway | 10.9.2014 |
| EU/1/14/941 | Vizamyl | Iceland | 11.9.2014 |
| EU/1/14/941 | Vizamyl | Liechtenstein | 31.8.2014 |
| EU/1/14/941 | Vizamyl | Norway | 12.9.2014 |
| EU/1/14/942 | Clopidogrel/Acetylsalicylic acid Teva | Iceland | 12.9.2014 |
| EU/1/14/942 | Clopidogrel/Acetylsalicylic acid Teva | Norway | 25.9.2014 |
| EU/1/14/942 | Clopidogrel/Acetylsalicylsäure Teva | Liechtenstein | 31.10.2014 |
| EU/1/14/943 | Velphoro | Iceland | 11.9.2014 |
| EU/1/14/943 | Velphoro | Liechtenstein | 31.8.2014 |
| EU/1/14/943 | Velphoro | Norway | 18.9.2014 |
| EU/1/14/944 | ABASRIA | Iceland | 24.9.2014 |
| EU/1/14/944 | ABASRIA | Liechtenstein | 31.10.2014 |
| EU/1/14/944 | ABASRIA | Norway | 24.9.2014 |
| EU/1/14/945 | IMBRUVICA | Iceland | 18.11.2014 |
| EU/1/14/945 | IMBRUVICA | Liechtenstein | 31.10.2014 |
| EU/1/14/945 | IMBRUVICA | Norway | 3.11.2014 |
| EU/1/14/946 | Accofil | Iceland | 26.9.2014 |
| EU/1/14/946 | Accofil | Liechtenstein | 31.10.2014 |
| EU/1/14/946 | Accofil | Norway | 14.10.2014 |
| EU/1/14/947 | Xultophy | Iceland | 25.9.2014 |
| EU/1/14/947 | Xultophy | Liechtenstein | 31.10.2014 |
| EU/1/14/947 | Xultophy | Norway | 25.9.2014 |
| EU/1/14/948 | Budesonide/Formoterol Teva | Iceland | 16.12.2014 |
| EU/1/14/948 | Budesonide/Formoterol Teva | Liechtenstein | 31.12.2014 |
| EU/1/14/948 | Budesonide/Formoterol Teva | Norway | 9.12.2014 |
| EU/1/14/949 | Vylaer Spiromax | Iceland | 12.12.2014 |
| EU/1/14/949 | Vylaer Spiromax | Liechtenstein | 31.12.2014 |
| EU/1/14/949 | Vylaer Spiromax | Norway | 9.12.2014 |
| EU/1/14/950 | Budesonide/Formoterol Teva Pharma B.V. | Iceland | 16.12.2014 |
| EU/1/14/950 | Budesonide/Formoterol Teva Pharma B.V. | Liechtenstein | 31.12.2014 |
| EU/1/14/950 | Budesonide/Formoterol Teva Pharma B.V. | Norway | 9.12.2014 |
| EU/1/14/951 | Busulfan Fresenius Kabi | Iceland | 25.9.2014 |
| EU/1/14/951 | Busulfan Fresenius Kabi | Liechtenstein | 31.10.2014 |
| EU/1/14/951 | Busulfan Fresenius Kabi | Norway | 2.10.2014 |
| EU/1/14/954 | Vargatef | Iceland | 20.12.2014 |
| EU/1/14/954 | Vargatef | Liechtenstein | 31.12.2014 |
| EU/1/14/954 | Vargatef | Norway | 1.12.2014 |
| EU/1/14/955 | Lymphoseek | Iceland | 19.12.2014 |
| EU/1/14/955 | Lymphoseek | Liechtenstein | 31.12.2014 |
| EU/1/14/955 | Lymphoseek | Norway | 10.12.2014 |
| EU/1/14/956 | Trulicity | Iceland | 20.12.2014 |
| EU/1/14/956 | Trulicity | Liechtenstein | 31.12.2014 |
| EU/1/14/956 | Trulicity | Norway | 1.12.2014 |
| EU/1/14/958 | Harvoni | Iceland | 9.12.2014 |
| EU/1/14/958 | Harvoni | Liechtenstein | 31.12.2014 |
| EU/1/14/958 | Harvoni | Norway | 3.12.2014 |
| EU/1/14/959 | Lynparza | Liechtenstein | 31.12.2014 |
| EU/1/14/960 | DUAVIVE | Liechtenstein | 31.12.2014 |
| EU/1/14/961 | Tadalafil Mylan | Iceland | 19.12.2014 |
| EU/1/14/961 | Tadalafil Mylan | Liechtenstein | 31.12.2014 |
| EU/1/14/961 | Tadalafil Mylan | Norway | 9.12.2014 |
| EU/1/14/962 | Moventig | Iceland | 20.12.2014 |
| EU/1/14/962 | Moventig | Liechtenstein | 31.12.2014 |
| EU/1/14/962 | Moventig | Norway | 12.12.2014 |
| EU/1/14/963 | Brimica Genuair | Iceland | 19.12.2014 |
| EU/1/14/963 | Brimica Genuair | Liechtenstein | 31.12.2014 |
| EU/1/14/963 | Brimica Genuair | Norway | 8.12.2014 |
| EU/1/14/964 | Duaklir Genuair | Iceland | 19.12.2014 |
| EU/1/14/964 | Duaklir Genuair | Liechtenstein | 31.12.2014 |
| EU/1/14/964 | Duaklir Genuair | Norway | 8.12.2014 |
| EU/1/14/965 | Ketoconazole HRA | Norway | 8.12.2014 |
| EU/1/14/965 | Ketoconazole HRA | Iceland | 19.12.2014 |
| EU/1/14/965 | Ketoconazole HRA | Liechtenstein | 31.12.2014 |
| EU/1/14/967 | REZOLSTA | Iceland | 17.12.2014 |
| EU/1/14/967 | REZOLSTA | Liechtenstein | 31.12.2014 |
| EU/1/14/967 | REZOLSTA | Norway | 4.12.2014 |
| EU/1/14/969 | Scenesse | Liechtenstein | 31.12.2014 |
| EU/1/14/970 | Rixubis | Liechtenstein | 31.12.2014 |
| EU/1/14/971 | Paliperidone Janssen | Iceland | 5.12.2014 |
| EU/1/14/971 | Paliperidone Janssen | Liechtenstein | 31.12.2014 |
| EU/1/14/971 | Paliperidone Janssen | Norway | 19.12.2014 |
| EU/1/14/972 | Duloxetin Lilly | Liechtenstein | 31.12.2014 |
| EU/1/14/972 | Duloxetine Lilly | Norway | 17.12.2014 |
| EU/2/09/101 | Zolvix | Liechtenstein | 31.12.2014 |
| EU/2/13/150 | Oncept IL-2 | Norway | 26.9.2014 |
| EU/2/14/163 | Versican Plus DHPPi/L4R | Norway | 10.7.2014 |
| EU/2/14/164 | Versican Plus DHPPi/L4 | Norway | 21.7.2014 |
| EU/2/14/165 | Vectra Felis | Norway | 10.7.2014 |
| EU/2/14/166 | ERYSENG | Iceland | 21.7.2014 |
| EU/2/14/166 | Eryseng | Norway | 5.8.2014 |
| EU/2/14/166 | ERYSENG | Liechtenstein | 31.8.2014 |
| EU/2/14/167 | ERYSENG PARVO | Iceland | 12.8.2014 |
| EU/2/14/167 | Eryseng Parvo | Norway | 5.8.2014 |
| EU/2/14/167 | ERYSENG PARVO | Liechtenstein | 31.8.2014 |
| EU/2/14/168 | Versican Plus Pi | Iceland | 21.7.2014 |
| EU/2/14/168 | Versican Plus Pi | Liechtenstein | 31.8.2014 |
| EU/2/14/168 | Versican Plus Pi | Norway | 5.8.2014 |
| EU/2/14/169 | Versican Plus DHPPi | Iceland | 21.7.2014 |
| EU/2/14/169 | Versican Plus DHPPi | Liechtenstein | 31.8.2014 |
| EU/2/14/169 | Versican Plus DHPPi | Norway | 5.8.2014 |
| EU/2/14/170 | OSURNIA | Iceland | 2.9.2014 |
| EU/2/14/170 | Osurnia | Liechtenstein | 31.8.2014 |
| EU/2/14/170 | Osurnia | Norway | 22.9.2014 |
| EU/2/14/171 | Versican Plus L4 | Iceland | 2.9.2014 |
| EU/2/14/171 | Versican Plus L4 | Liechtenstein | 31.8.2014 |
| EU/2/14/171 | Versican Plus L4 | Norway | 11.11.2014 |
| EU/2/14/172 | Versican Plus Pi/L4 | Iceland | 2.9.2014 |
| EU/2/14/172 | Versican Plus Pi/L4 | Liechtenstein | 31.8.2014 |
| EU/2/14/172 | Versican Plus Pi/L4 | Norway | 11.11.2014 |
| EU/2/14/173 | Versican Plus Pi/L4R | Norway | 11.11.2014 |
| EU/2/14/173 | Versican Plus Pi/L4R | Iceland | 31.7.2014 |
| EU/2/14/174 | Nobilis IB Primo QX | Iceland | 24.9.2014 |
| EU/2/14/174 | Nobilis IB Primo QX | Liechtenstein | 31.10.2014 |
| EU/2/14/174 | Nobilis IB Primo QX | Norway | 11.11.2014 |
| EU/2/14/175 | Porcilis PCV M Hyo | Norway | 15.12.2014 |
| EU/2/14/175 | Porcilis PCV M Hyo | Iceland | 4.12.2014 |
| EU/2/14/175 | Porcilis PCV M Hyo | Liechtenstein | 31.12.2014 |
| EU/2/14/176 | Bovela | Liechtenstein | 31.12.2014 |

EU Number

Product

Country

Date of authorisation

EU/1/09/527

Ribavirin Teva Pharma BV

Liechtenstein

31.12.2014

EU/1/09/585

Rivastigmine 1A Pharma

Liechtenstein

31.10.2014

EU/1/09/591

Multaq

Liechtenstein

31.10.2014

EU/1/09/595

Sildenafil Actavis

Liechtenstein

31.10.2014

EU/1/09/598

Nevirapine Teva

Liechtenstein

31.8.2014

EU/1/09/599

Rivastigmine Sandoz

Liechtenstein

31.8.2014

EU/1/09/600

Zutectra

Liechtenstein

31.10.2014

EU/1/11/688

Cinryze

Liechtenstein

31.12.2014

EU/1/11/705

Vibativ

Iceland

27.10.2014

EU/1/12/772

Zoledronsäure Teva Pharma

Liechtenstein

31.12.2014

EU/1/13/902

Translarna

Iceland

15.8.2014

EU/1/13/902

Translarna

Liechtenstein

31.8.2014

EU/1/13/902

Translarna

Norway

12.8.2014

EU/1/14/917

Ulunar Breezhaler

Iceland

22.7.2014

EU/1/14/931

Mekinist

Iceland

21.7.2014

EU/1/14/931

Mekinist

Liechtenstein

31.8.2014

EU/1/14/931

Mekinist

Norway

14.7.2014

EU/1/14/933

Simbrinza

Liechtenstein

31.8.2014

EU/1/14/933

Simbrinza

Norway

7.8.2014

EU/1/14/933

Simbrinza

Iceland

14.8.2014

EU/1/14/934

Plegridy

Iceland

15.8.2014

EU/1/14/934

Plegridy

Liechtenstein

31.8.2014

EU/1/14/934

Plegridy

Norway

13.8.2014

EU/1/14/935

Envarsus

Iceland

14.8.2014

EU/1/14/935

Envarsus

Liechtenstein

31.8.2014

EU/1/14/935

Envarsus

Norway

13.8.2014

EU/1/14/936

Nuwiq

Iceland

10.10.2014

EU/1/14/936

Nuwiq

Norway

18.8.2014

EU/1/14/937

Gazyvaro

Iceland

14.8.2014

EU/1/14/937

Gazyvaro

Liechtenstein

31.8.2014

EU/1/14/937

Gazyvaro

Norway

13.8.2014

EU/1/14/938

Zydelig

Iceland

25.9.2014

EU/1/14/938

Zydelig

Liechtenstein

31.10.2014

EU/1/14/938

Zydelig

Norway

2.10.2014

EU/1/14/939

Daklinza

Iceland

11.9.2014

EU/1/14/939

Daklinza

Liechtenstein

31.8.2014

EU/1/14/939

Daklinza

Norway

9.9.2014

EU/1/14/940

Triumeq

Iceland

12.9.2014

EU/1/14/940

Triumeq

Liechtenstein

31.10.2014

EU/1/14/940

Triumeq

Norway

10.9.2014

EU/1/14/941

Vizamyl

Iceland

11.9.2014

EU/1/14/941

Vizamyl

Liechtenstein

31.8.2014

EU/1/14/941

Vizamyl

Norway

12.9.2014

EU/1/14/942

Clopidogrel/Acetylsalicylic acid Teva

Iceland

12.9.2014

EU/1/14/942

Clopidogrel/Acetylsalicylic acid Teva

Norway

25.9.2014

EU/1/14/942

Clopidogrel/Acetylsalicylsäure Teva

Liechtenstein

31.10.2014

EU/1/14/943

Velphoro

Iceland

11.9.2014

EU/1/14/943

Velphoro

Liechtenstein

31.8.2014

EU/1/14/943

Velphoro

Norway

18.9.2014

EU/1/14/944

ABASRIA

Iceland

24.9.2014

EU/1/14/944

ABASRIA

Liechtenstein

31.10.2014

EU/1/14/944

ABASRIA

Norway

24.9.2014

EU/1/14/945

IMBRUVICA

Iceland

18.11.2014

EU/1/14/945

IMBRUVICA

Liechtenstein

31.10.2014

EU/1/14/945

IMBRUVICA

Norway

3.11.2014

EU/1/14/946

Accofil

Iceland

26.9.2014

EU/1/14/946

Accofil

Liechtenstein

31.10.2014

EU/1/14/946

Accofil

Norway

14.10.2014

EU/1/14/947

Xultophy

Iceland

25.9.2014

EU/1/14/947

Xultophy

Liechtenstein

31.10.2014

EU/1/14/947

Xultophy

Norway

25.9.2014

EU/1/14/948

Budesonide/Formoterol Teva

Iceland

16.12.2014

EU/1/14/948

Budesonide/Formoterol Teva

Liechtenstein

31.12.2014

EU/1/14/948

Budesonide/Formoterol Teva

Norway

9.12.2014

EU/1/14/949

Vylaer Spiromax

Iceland

12.12.2014

EU/1/14/949

Vylaer Spiromax

Liechtenstein

31.12.2014

EU/1/14/949

Vylaer Spiromax

Norway

9.12.2014

EU/1/14/950

Budesonide/Formoterol Teva Pharma B.V.

Iceland

16.12.2014

EU/1/14/950

Budesonide/Formoterol Teva Pharma B.V.

Liechtenstein

31.12.2014

EU/1/14/950

Budesonide/Formoterol Teva Pharma B.V.

Norway

9.12.2014

EU/1/14/951

Busulfan Fresenius Kabi

Iceland

25.9.2014

EU/1/14/951

Busulfan Fresenius Kabi

Liechtenstein

31.10.2014

EU/1/14/951

Busulfan Fresenius Kabi

Norway

2.10.2014

EU/1/14/954

Vargatef

Iceland

20.12.2014

EU/1/14/954

Vargatef

Liechtenstein

31.12.2014

EU/1/14/954

Vargatef

Norway

1.12.2014

EU/1/14/955

Lymphoseek

Iceland

19.12.2014

EU/1/14/955

Lymphoseek

Liechtenstein

31.12.2014

EU/1/14/955

Lymphoseek

Norway

10.12.2014

EU/1/14/956

Trulicity

Iceland

20.12.2014

EU/1/14/956

Trulicity

Liechtenstein

31.12.2014

EU/1/14/956

Trulicity

Norway

1.12.2014

EU/1/14/958

Harvoni

Iceland

9.12.2014

EU/1/14/958

Harvoni

Liechtenstein

31.12.2014

EU/1/14/958

Harvoni

Norway

3.12.2014

EU/1/14/959

Lynparza

Liechtenstein

31.12.2014

EU/1/14/960

DUAVIVE

Liechtenstein

31.12.2014

EU/1/14/961

Tadalafil Mylan

Iceland

19.12.2014

EU/1/14/961

Tadalafil Mylan

Liechtenstein

31.12.2014

EU/1/14/961

Tadalafil Mylan

Norway

9.12.2014

EU/1/14/962

Moventig

Iceland

20.12.2014

EU/1/14/962

Moventig

Liechtenstein

31.12.2014

EU/1/14/962

Moventig

Norway

12.12.2014

EU/1/14/963

Brimica Genuair

Iceland

19.12.2014

EU/1/14/963

Brimica Genuair

Liechtenstein

31.12.2014

EU/1/14/963

Brimica Genuair

Norway

8.12.2014

EU/1/14/964

Duaklir Genuair

Iceland

19.12.2014

EU/1/14/964

Duaklir Genuair

Liechtenstein

31.12.2014

EU/1/14/964

Duaklir Genuair

Norway

8.12.2014

EU/1/14/965

Ketoconazole HRA

Norway

8.12.2014

EU/1/14/965

Ketoconazole HRA

Iceland

19.12.2014

EU/1/14/965

Ketoconazole HRA

Liechtenstein

31.12.2014

EU/1/14/967

REZOLSTA

Iceland

17.12.2014

EU/1/14/967

REZOLSTA

Liechtenstein

31.12.2014

EU/1/14/967

REZOLSTA

Norway

4.12.2014

EU/1/14/969

Scenesse

Liechtenstein

31.12.2014

EU/1/14/970

Rixubis

Liechtenstein

31.12.2014

EU/1/14/971

Paliperidone Janssen

Iceland

5.12.2014

EU/1/14/971

Paliperidone Janssen

Liechtenstein

31.12.2014

EU/1/14/971

Paliperidone Janssen

Norway

19.12.2014

EU/1/14/972

Duloxetin Lilly

Liechtenstein

31.12.2014

EU/1/14/972

Duloxetine Lilly

Norway

17.12.2014

EU/2/09/101

Zolvix

Liechtenstein

31.12.2014

EU/2/13/150

Oncept IL-2

Norway

26.9.2014

EU/2/14/163

Versican Plus DHPPi/L4R

Norway

10.7.2014

EU/2/14/164

Versican Plus DHPPi/L4

Norway

21.7.2014

EU/2/14/165

Vectra Felis

Norway

10.7.2014

EU/2/14/166

ERYSENG

Iceland

21.7.2014

EU/2/14/166

Eryseng

Norway

5.8.2014

EU/2/14/166

ERYSENG

Liechtenstein

31.8.2014

EU/2/14/167

ERYSENG PARVO

Iceland

12.8.2014

EU/2/14/167

Eryseng Parvo

Norway

5.8.2014

EU/2/14/167

ERYSENG PARVO

Liechtenstein

31.8.2014

EU/2/14/168

Versican Plus Pi

Iceland

21.7.2014

EU/2/14/168

Versican Plus Pi

Liechtenstein

31.8.2014

EU/2/14/168

Versican Plus Pi

Norway

5.8.2014

EU/2/14/169

Versican Plus DHPPi

Iceland

21.7.2014

EU/2/14/169

Versican Plus DHPPi

Liechtenstein

31.8.2014

EU/2/14/169

Versican Plus DHPPi

Norway

5.8.2014

EU/2/14/170

OSURNIA

Iceland

2.9.2014

EU/2/14/170

Osurnia

Liechtenstein

31.8.2014

EU/2/14/170

Osurnia

Norway

22.9.2014

EU/2/14/171

Versican Plus L4

Iceland

2.9.2014

EU/2/14/171

Versican Plus L4

Liechtenstein

31.8.2014

EU/2/14/171

Versican Plus L4

Norway

11.11.2014

EU/2/14/172

Versican Plus Pi/L4

Iceland

2.9.2014

EU/2/14/172

Versican Plus Pi/L4

Liechtenstein

31.8.2014

EU/2/14/172

Versican Plus Pi/L4

Norway

11.11.2014

EU/2/14/173

Versican Plus Pi/L4R

Norway

11.11.2014

EU/2/14/173

Versican Plus Pi/L4R

Iceland

31.7.2014

EU/2/14/174

Nobilis IB Primo QX

Iceland

24.9.2014

EU/2/14/174

Nobilis IB Primo QX

Liechtenstein

31.10.2014

EU/2/14/174

Nobilis IB Primo QX

Norway

11.11.2014

EU/2/14/175

Porcilis PCV M Hyo

Norway

15.12.2014

EU/2/14/175

Porcilis PCV M Hyo

Iceland

4.12.2014

EU/2/14/175

Porcilis PCV M Hyo

Liechtenstein

31.12.2014

EU/2/14/176

Bovela

Liechtenstein

31.12.2014

---

ANNEX II

List of renewed marketing authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 July – 31 December 2014:

| EU Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/04/287 | Osseor | Iceland | 16.9.2014 |
| EU/1/04/288 | Protelos | Iceland | 16.9.2014 |
| EU/1/04/289 | Angiox | Iceland | 18.7.2014 |
| EU/1/04/289 | Angiox | Norway | 8.7.2014 |
| EU/1/04/295 | Xagrid | Liechtenstein | 31.8.2014 |
| EU/1/04/295 | Xagrid | Iceland | 14.8.2014 |
| EU/1/04/295 | Xagrid | Norway | 7.8.2014 |
| EU/1/04/298 | Kivexa | Liechtenstein | 31.12.2014 |
| EU/1/04/298 | Kivexa | Iceland | 10.12.2014 |
| EU/1/04/298 | Kivexa | Norway | 17.12.2014 |
| EU/1/04/299 | Fendrix | Liechtenstein | 31.12.2014 |
| EU/1/04/299 | Fendrix | Iceland | 9.12.2014 |
| EU/1/04/299 | Fendrix | Norway | 4.12.2014 |
| EU/1/04/300 | Avastin | Liechtenstein | 31.12.2014 |
| EU/1/04/300 | Avastin | Iceland | 12.12.2014 |
| EU/1/04/300 | Avastin | Norway | 28.11.2014 |
| EU/1/04/302 | Prialt | Liechtenstein | 31.10.2014 |
| EU/1/04/302 | Prialt | Iceland | 24.9.2014 |
| EU/1/04/302 | Prialt | Norway | 26.9.2014 |
| EU/1/09/511 | Conbriza | Iceland | 16.9.2014 |
| EU/1/09/530 | Repaglinide Teva | Iceland | 16.7.2014 |
| EU/1/09/530 | Repaglinide Teva | Norway | 1.7.2014 |
| EU/1/09/539 | Samsca | Iceland | 18.7.2014 |
| EU/1/09/539 | Samsca | Norway | 1.7.2014 |
| EU/1/09/545 | Onglyza | Liechtenstein | 31.8.2014 |
| EU/1/09/545 | Onglyza | Iceland | 14.8.2014 |
| EU/1/09/545 | Onglyza | Norway | 25.8.2014 |
| EU/1/09/546 | Simponi | Iceland | 18.7.2014 |
| EU/1/09/546 | Simponi | Norway | 10.7.2014 |
| EU/1/09/550 | Javlor | Iceland | 22.7.2014 |
| EU/1/09/552 | Topotecan Teva | Iceland | 18.7.2014 |
| EU/1/09/552 | Topotecan Teva | Norway | 10.7.2014 |
| EU/1/09/555 | Clopidogrel TAD | Iceland | 22.7.2014 |
| EU/1/09/555 | Clopidogrel TAD | Norway | 1.7.2014 |
| EU/1/09/559 | Clopidogrel Mylan | Norway | 1.7.2014 |
| EU/1/09/560 | Clopidogrel DURA | Norway | 1.7.2014 |
| EU/1/09/562 | Clopidogrel Krka d.d. | Iceland | 22.7.2014 |
| EU/1/09/562 | Clopidogrel Krka d.d. | Norway | 1.7.2014 |
| EU/1/09/563 | ChondroCelect | Liechtenstein | 31.8.2014 |
| EU/1/09/563 | ChondroCelect | Iceland | 9.9.2014 |
| EU/1/09/563 | ChondroCelect | Norway | 10.9.2014 |
| EU/1/09/564 | Ilaris | Iceland | 18.7.2014 |
| EU/1/09/564 | Ilaris | Norway | 10.7.2014 |
| EU/1/09/565 | Biopoin | Liechtenstein | 31.10.2014 |
| EU/1/09/565 | Biopoin | Iceland | 10.9.2014 |
| EU/1/09/565 | Biopoin | Norway | 8.9.2014 |
| EU/1/09/566 | Lamivudine Teva | Liechtenstein | 31.10.2014 |
| EU/1/09/566 | Lamivudine Teva | Iceland | 23.9.2014 |
| EU/1/09/566 | Lamivudine Teva | Norway | 9.10.2014 |
| EU/1/09/568 | Clopidogrel Apotex | Liechtenstein | 31.10.2014 |
| EU/1/09/568 | Clopidogrel Apotex | Iceland | 25.9.2014 |
| EU/1/09/568 | Clopidogrel Apotex | Norway | 29.9.2014 |
| EU/1/09/569 | Exforge HCT | Liechtenstein | 31.8.2014 |
| EU/1/09/569 | Exforge HCT | Iceland | 18.7.2014 |
| EU/1/09/569 | Exforge HCT | Norway | 29.7.2014 |
| EU/1/09/572 | Vantavo | Liechtenstein | 31.10.2014 |
| EU/1/09/572 | Vantavo | Iceland | 25.9.2014 |
| EU/1/09/572 | Vantavo | Norway | 26.9.2014 |
| EU/1/09/573 | Eporatio | Liechtenstein | 31.10.2014 |
| EU/1/09/573 | Eporatio | Iceland | 24.9.2014 |
| EU/1/09/573 | Eporatio | Norway | 29.9.2014 |
| EU/1/09/574 | Dafiro HCT | Liechtenstein | 31.8.2014 |
| EU/1/09/574 | Dafiro HCT | Iceland | 22.7.2014 |
| EU/1/09/574 | Dafiro HCT | Norway | 4.8.2014 |
| EU/1/09/575 | Copalia HCT | Liechtenstein | 31.8.2014 |
| EU/1/09/575 | Copalia HCT | Iceland | 22.7.2014 |
| EU/1/09/575 | Copalia HCT | Norway | 4.8.2014 |
| EU/1/09/576 | Irbesartan Teva | Liechtenstein | 31.8.2014 |
| EU/1/09/576 | Irbesartan Teva | Iceland | 13.8.2014 |
| EU/1/09/576 | Irbesartan Teva | Norway | 4.8.2014 |
| EU/1/09/577 | Foclivia | Liechtenstein | 31.8.2014 |
| EU/1/09/577 | Foclivia | Iceland | 21.7.2014 |
| EU/1/09/577 | Foclivia | Norway | 29.7.2014 |
| EU/1/09/578 | Adjupanrix | Liechtenstein | 31.8.2014 |
| EU/1/09/578 | Adjupanrix | Iceland | 14.8.2014 |
| EU/1/09/578 | Adjupanrix | Norway | 13.8.2014 |
| EU/1/09/579 | Repaglinide Krka | Liechtenstein | 31.10.2014 |
| EU/1/09/579 | Repaglinide Krka | Iceland | 10.9.2014 |
| EU/1/09/579 | Repaglinide Krka | Norway | 9.9.2014 |
| EU/1/09/580 | Enyglid | Liechtenstein | 31.8.2014 |
| EU/1/09/580 | Enyglid | Iceland | 9.9.2014 |
| EU/1/09/580 | Enyglid | Norway | 10.9.2014 |
| EU/1/09/581 | Resolor | Norway | 1.7.2014 |
| EU/1/09/583 | Irbesartan/Hydrochlorothiazid | Liechtenstein | 31.12.2014 |
| EU/1/09/583 | Irbesartan/Hydrochlorothiazide Teva | Iceland | 9.12.2014 |
| EU/1/09/583 | Irbesartan/Hydrochlorotiazide Teva | Norway | 27.11.2014 |
| EU/1/09/584 | Sildenafil Teva | Liechtenstein | 31.10.2014 |
| EU/1/09/584 | Sildenafil Teva | Iceland | 23.9.2014 |
| EU/1/09/584 | Sildenafil Teva | Norway | 2.10.2014 |
| EU/1/09/585 | Rivastigmine 1A Pharma | Iceland | 9.9.2014 |
| EU/1/09/585 | Rivastigmine 1A Pharma | Norway | 10.9.2014 |
| EU/1/09/586 | Oslif Breezhaler | Liechtenstein | 31.10.2014 |
| EU/1/09/586 | Oslif Breezhaler | Iceland | 25.9.2014 |
| EU/1/09/586 | Oslif Breezhaler | Norway | 14.10.2014 |
| EU/1/09/587 | Olanzapine Glenmark | Liechtenstein | 31.8.2014 |
| EU/1/09/587 | Olanzapine Glenmark | Iceland | 9.9.2014 |
| EU/1/09/587 | Olanzapine Glenmark | Norway | 10.9.2014 |
| EU/1/09/588 | Olanzapine Glenmark Europe | Liechtenstein | 31.8.2014 |
| EU/1/09/588 | Olanzapine Glenmark Europe | Iceland | 9.9.2014 |
| EU/1/09/588 | Olanzapine Glenmark Europe | Norway | 10.9.2014 |
| EU/1/09/589 | Rivastigmine HEXAL | Liechtenstein | 31.8.2014 |
| EU/1/09/589 | Rivastigmine HEXAL | Iceland | 13.8.2014 |
| EU/1/09/589 | Rivastigmine Hexal | Norway | 13.8.2014 |
| EU/1/09/590 | Prevenar 13 | Liechtenstein | 31.12.2014 |
| EU/1/09/590 | Prevenar 13 | Iceland | 10.10.2014 |
| EU/1/09/590 | Prevenar 13 | Norway | 15.10.2014 |
| EU/1/09/591 | Multaq | Norway | 29.9.2014 |
| EU/1/09/591 | Multaq | Iceland | 26.9.2014 |
| EU/1/09/592 | Olazax Disperzi | Liechtenstein | 31.8.2014 |
| EU/1/09/592 | Olazax Disperzi | Iceland | 4.9.2014 |
| EU/1/09/592 | Olazax Disperzi | Norway | 27.8.2014 |
| EU/1/09/593 | Onbrez Breezhaler | Liechtenstein | 31.10.2014 |
| EU/1/09/593 | Onbrez Breezhaler | Iceland | 25.9.2014 |
| EU/1/09/593 | Onbrez Breezhaler | Norway | 14.10.2014 |
| EU/1/09/594 | Hirobrez Breezhaler | Norway | 14.10.2014 |
| EU/1/09/594 | Hirobriz Breezhaler | Liechtenstein | 31.10.2014 |
| EU/1/09/594 | Hirobriz Breezhaler | Iceland | 25.9.2014 |
| EU/1/09/595 | Sildenafil Actavis | Iceland | 23.9.2014 |
| EU/1/09/595 | Sildenafil Actavis | Norway | 1.10.2014 |
| EU/1/09/596 | Lamivudine Teva Pharma B.V. | Liechtenstein | 31.10.2014 |
| EU/1/09/596 | Lamivudine Teva Pharma B.V. | Iceland | 23.9.2014 |
| EU/1/09/596 | Lamivudine Teva Pharma B.V. | Norway | 9.10.2014 |
| EU/1/09/597 | Olazax | Iceland | 9.9.2014 |
| EU/1/09/597 | Olazax | Norway | 10.9.2014 |
| EU/1/09/598 | Nevirapine Teva | Iceland | 10.9.2014 |
| EU/1/09/598 | Nevirapine Teva | Norway | 9.9.2014 |
| EU/1/09/599 | Rivastigmine Sandoz | Iceland | 13.8.2014 |
| EU/1/09/599 | Rivastigmine Sandoz | Norway | 13.8.2014 |
| EU/1/09/600 | Zutectra | Iceland | 24.9.2014 |
| EU/1/09/600 | Zutectra | Norway | 15.10.2014 |
| EU/1/09/601 | Firdapse | Norway | 18.12.2014 |
| EU/1/09/602 | Scintimun | Liechtenstein | 31.8.2014 |
| EU/1/09/602 | Scintimun | Iceland | 10.9.2014 |
| EU/1/09/602 | Scintimun | Norway | 18.9.2014 |
| EU/1/09/603 | Sildenafil ratiopharm | Liechtenstein | 31.10.2014 |
| EU/1/09/603 | Sildenafil ratiopharm | Iceland | 23.9.2014 |
| EU/1/09/603 | Sildenafil ratiopharm | Norway | 2.10.2014 |
| EU/1/09/604 | Leflunomide Winthrop | Liechtenstein | 31.12.2014 |
| EU/1/09/604 | Leflunomide Winthrop | Iceland | 12.12.2014 |
| EU/1/09/604 | Leflunomide Winthrop | Norway | 28.11.2014 |
| EU/1/09/605 | Temomedac | Liechtenstein | 31.8.2014 |
| EU/1/09/605 | Temomedac | Iceland | 13.8.2014 |
| EU/1/09/605 | Temomedac | Norway | 7.8.2014 |
| EU/1/09/606 | Temozolomide Teva | Liechtenstein | 31.10.2014 |
| EU/1/09/606 | Temozolomide Teva | Iceland | 10.9.2014 |
| EU/1/09/606 | Temozolomide Teva | Norway | 12.9.2014 |
| EU/1/09/607 | Silodyx | Liechtenstein | 31.10.2014 |
| EU/1/09/607 | Silodyx | Iceland | 25.9.2014 |
| EU/1/09/607 | Silodyx | Norway | 15.10.2014 |
| EU/1/09/608 | Urorec | Liechtenstein | 31.10.2014 |
| EU/1/09/608 | Urorec | Iceland | 25.9.2014 |
| EU/1/09/608 | Urorec | Norway | 15.10.2014 |
| EU/1/09/609 | Elonva | Liechtenstein | 31.8.2014 |
| EU/1/09/609 | Elonva | Iceland | 10.9.2014 |
| EU/1/09/609 | Elonva | Norway | 8.9.2014 |
| EU/1/09/611 | Docetaxel Teva | Liechtenstein | 31.8.2014 |
| EU/1/09/611 | Docetaxel Teva | Iceland | 12.8.2014 |
| EU/1/09/611 | Docetaxel Teva | Norway | 6.8.2014 |
| EU/1/10/614 | Menveo | Liechtenstein | 31.12.2014 |
| EU/1/10/614 | Menveo | Iceland | 20.12.2014 |
| EU/1/10/614 | Menveo | Norway | 12.12.2014 |
| EU/1/10/616 | Temozolomide HEXAL | Liechtenstein | 31.12.2014 |
| EU/1/10/616 | Temozolomide Hexal | Iceland | 12.12.2014 |
| EU/1/10/616 | Temozolomide Hexal | Norway | 26.11.2014 |
| EU/1/10/617 | Temozolomid Sandoz | Liechtenstein | 31.12.2014 |
| EU/1/10/617 | Temozolomide Sandoz | Iceland | 16.12.2014 |
| EU/1/10/617 | Temozolomide Sandoz | Norway | 28.11.2014 |
| EU/1/10/619 | DuoPlavin | Liechtenstein | 31.12.2014 |
| EU/1/10/619 | DuoPlavin | Iceland | 18.12.2014 |
| EU/1/10/619 | DuoPlavin | Norway | 3.12.2014 |
| EU/1/10/620 | Ristfor | Liechtenstein | 31.12.2014 |
| EU/1/10/621 | Ristaben | Liechtenstein | 31.12.2014 |
| EU/1/10/622 | Tepadina | Liechtenstein | 31.12.2014 |
| EU/1/10/622 | Tepadina | Iceland | 10.12.2014 |
| EU/1/10/622 | Tepadina | Norway | 28.11.2014 |
| EU/1/10/623 | DuoCover | Liechtenstein | 31.12.2014 |
| EU/1/10/623 | DuoCover | Iceland | 18.12.2014 |
| EU/1/10/623 | DuoCover | Norway | 3.12.2014 |
| EU/1/11/710 | Votubia | Liechtenstein | 31.8.2014 |
| EU/1/11/710 | Votubia | Iceland | 12.8.2014 |
| EU/1/11/710 | Votubia | Norway | 7.8.2014 |
| EU/1/12/793 | XALKORI | Liechtenstein | 31.8.2014 |
| EU/1/12/793 | XALKORI | Iceland | 10.9.2014 |
| EU/1/12/793 | XALKORI | Norway | 5.9.2014 |
| EU/1/12/794 | ADCETRIS | Liechtenstein | 31.8.2014 |
| EU/1/12/794 | ADCETRIS | Iceland | 10.9.2014 |
| EU/1/12/794 | ADCETRIS | Norway | 5.9.2014 |
| EU/1/13/848 | Erivedge | Liechtenstein | 31.8.2014 |
| EU/1/13/848 | Erivedge | Iceland | 17.7.2014 |
| EU/1/13/848 | Erivedge | Norway | 5.8.2014 |
| EU/1/97/044 | Tasmar | Liechtenstein | 31.8.2014 |
| EU/1/97/044 | Tasmar | Iceland | 13.8.2014 |
| EU/1/97/044 | Tasmar | Norway | 13.8.2014 |
| EU/1/99/114 | Zeffix | Iceland | 18.7.2014 |
| EU/1/99/114 | Zeffix | Norway | 9.7.2014 |
| EU/1/99/123 | Renagel | Liechtenstein | 31.12.2014 |
| EU/1/99/123 | Renagel | Iceland | 17.12.2014 |
| EU/1/99/123 | Renagel | Norway | 10.12.2014 |
| EU/2/04/043 | Equilis StrepE | Norway | 10.7.2014 |
| EU/2/04/044 | Aivlosin | Liechtenstein | 31.10.2014 |
| EU/2/04/044 | Aivlosin | Iceland | 24.9.2014 |
| EU/2/04/044 | Aivlosin | Norway | 11.11.2014 |
| EU/2/08/086 | Equip WNV | Norway | 12.11.2014 |
| EU/2/08/087 | Masivet | Norway | 11.11.2014 |
| EU/2/09/094 | BTVPUR AlSap 8 | Norway | 21.7.2014 |
| EU/2/09/095 | Improvac | Norway | 11.11.2014 |
| EU/2/09/096 | Leucogen | Norway | 9.10.2014 |
| EU/2/09/097 | Leucofeligen FeLV/RCP | Norway | 9.10.2014 |
| EU/2/09/099 | Suvaxyn PCV | Norway | 21.7.2014 |
| EU/2/09/100 | Palladia | Norway | 11.11.2014 |
| EU/2/09/100 | Palladia | Liechtenstein | 31.8.2014 |
| EU/2/09/100 | Palladia | Iceland | 15.8.2014 |
| EU/2/09/101 | Zolvix | Iceland | 4.12.2014 |
| EU/2/09/101 | Zolvix | Norway | 17.12.2014 |
| EU/2/09/102 | Gripovac 3 | Norway | 17.12.2014 |
| EU/2/09/102 | Gripovac 3 | Liechtenstein | 31.12.2014 |
| EU/2/09/102 | Gripovac 3 | Iceland | 20.12.2014 |
| EU/2/09/103 | Respiporc Flu3 | Liechtenstein | 31.12.2014 |
| EU/2/09/103 | RESPIPORC FLU3 | Iceland | 20.12.2014 |
| EU/2/09/104 | Zulvac 8 Ovis | Liechtenstein | 31.12.2014 |
| EU/2/09/104 | Zulvac 8 Ovis | Iceland | 4.12.2014 |
| EU/2/09/105 | Zulvac 8 Bovis | Norway | 15.12.2014 |
| EU/2/09/105 | Zulvac 8 Bovis | Liechtenstein | 31.12.2014 |
| EU/2/09/105 | Zulvac 8 Bovis | Iceland | 4.12.2014 |

EU Number

Product

Country

Date of authorisation

EU/1/04/287

Osseor

Iceland

16.9.2014

EU/1/04/288

Protelos

Iceland

16.9.2014

EU/1/04/289

Angiox

Iceland

18.7.2014

EU/1/04/289

Angiox

Norway

8.7.2014

EU/1/04/295

Xagrid

Liechtenstein

31.8.2014

EU/1/04/295

Xagrid

Iceland

14.8.2014

EU/1/04/295

Xagrid

Norway

7.8.2014

EU/1/04/298

Kivexa

Liechtenstein

31.12.2014

EU/1/04/298

Kivexa

Iceland

10.12.2014

EU/1/04/298

Kivexa

Norway

17.12.2014

EU/1/04/299

Fendrix

Liechtenstein

31.12.2014

EU/1/04/299

Fendrix

Iceland

9.12.2014

EU/1/04/299

Fendrix

Norway

4.12.2014

EU/1/04/300

Avastin

Liechtenstein

31.12.2014

EU/1/04/300

Avastin

Iceland

12.12.2014

EU/1/04/300

Avastin

Norway

28.11.2014

EU/1/04/302

Prialt

Liechtenstein

31.10.2014

EU/1/04/302

Prialt

Iceland

24.9.2014

EU/1/04/302

Prialt

Norway

26.9.2014

EU/1/09/511

Conbriza

Iceland

16.9.2014

EU/1/09/530

Repaglinide Teva

Iceland

16.7.2014

EU/1/09/530

Repaglinide Teva

Norway

1.7.2014

EU/1/09/539

Samsca

Iceland

18.7.2014

EU/1/09/539

Samsca

Norway

1.7.2014

EU/1/09/545

Onglyza

Liechtenstein

31.8.2014

EU/1/09/545

Onglyza

Iceland

14.8.2014

EU/1/09/545

Onglyza

Norway

25.8.2014

EU/1/09/546

Simponi

Iceland

18.7.2014

EU/1/09/546

Simponi

Norway

10.7.2014

EU/1/09/550

Javlor

Iceland

22.7.2014

EU/1/09/552

Topotecan Teva

Iceland

18.7.2014

EU/1/09/552

Topotecan Teva

Norway

10.7.2014

EU/1/09/555

Clopidogrel TAD

Iceland

22.7.2014

EU/1/09/555

Clopidogrel TAD

Norway

1.7.2014

EU/1/09/559

Clopidogrel Mylan

Norway

1.7.2014

EU/1/09/560

Clopidogrel DURA

Norway

1.7.2014

EU/1/09/562

Clopidogrel Krka d.d.

Iceland

22.7.2014

EU/1/09/562

Clopidogrel Krka d.d.

Norway

1.7.2014

EU/1/09/563

ChondroCelect

Liechtenstein

31.8.2014

EU/1/09/563

ChondroCelect

Iceland

9.9.2014

EU/1/09/563

ChondroCelect

Norway

10.9.2014

EU/1/09/564

Ilaris

Iceland

18.7.2014

EU/1/09/564

Ilaris

Norway

10.7.2014

EU/1/09/565

Biopoin

Liechtenstein

31.10.2014

EU/1/09/565

Biopoin

Iceland

10.9.2014

EU/1/09/565

Biopoin

Norway

8.9.2014

EU/1/09/566

Lamivudine Teva

Liechtenstein

31.10.2014

EU/1/09/566

Lamivudine Teva

Iceland

23.9.2014

EU/1/09/566

Lamivudine Teva

Norway

9.10.2014

EU/1/09/568

Clopidogrel Apotex

Liechtenstein

31.10.2014

EU/1/09/568

Clopidogrel Apotex

Iceland

25.9.2014

EU/1/09/568

Clopidogrel Apotex

Norway

29.9.2014

EU/1/09/569

Exforge HCT

Liechtenstein

31.8.2014

EU/1/09/569

Exforge HCT

Iceland

18.7.2014

EU/1/09/569

Exforge HCT

Norway

29.7.2014

EU/1/09/572

Vantavo

Liechtenstein

31.10.2014

EU/1/09/572

Vantavo

Iceland

25.9.2014

EU/1/09/572

Vantavo

Norway

26.9.2014

EU/1/09/573

Eporatio

Liechtenstein

31.10.2014

EU/1/09/573

Eporatio

Iceland

24.9.2014

EU/1/09/573

Eporatio

Norway

29.9.2014

EU/1/09/574

Dafiro HCT

Liechtenstein

31.8.2014

EU/1/09/574

Dafiro HCT

Iceland

22.7.2014

EU/1/09/574

Dafiro HCT

Norway

4.8.2014

EU/1/09/575

Copalia HCT

Liechtenstein

31.8.2014

EU/1/09/575

Copalia HCT

Iceland

22.7.2014

EU/1/09/575

Copalia HCT

Norway

4.8.2014

EU/1/09/576

Irbesartan Teva

Liechtenstein

31.8.2014

EU/1/09/576

Irbesartan Teva

Iceland

13.8.2014

EU/1/09/576

Irbesartan Teva

Norway

4.8.2014

EU/1/09/577

Foclivia

Liechtenstein

31.8.2014

EU/1/09/577

Foclivia

Iceland

21.7.2014

EU/1/09/577

Foclivia

Norway

29.7.2014

EU/1/09/578

Adjupanrix

Liechtenstein

31.8.2014

EU/1/09/578

Adjupanrix

Iceland

14.8.2014

EU/1/09/578

Adjupanrix

Norway

13.8.2014

EU/1/09/579

Repaglinide Krka

Liechtenstein

31.10.2014

EU/1/09/579

Repaglinide Krka

Iceland

10.9.2014

EU/1/09/579

Repaglinide Krka

Norway

9.9.2014

EU/1/09/580

Enyglid

Liechtenstein

31.8.2014

EU/1/09/580

Enyglid

Iceland

9.9.2014

EU/1/09/580

Enyglid

Norway

10.9.2014

EU/1/09/581

Resolor

Norway

1.7.2014

EU/1/09/583

Irbesartan/Hydrochlorothiazid

Liechtenstein

31.12.2014

EU/1/09/583

Irbesartan/Hydrochlorothiazide Teva

Iceland

9.12.2014

EU/1/09/583

Irbesartan/Hydrochlorotiazide Teva

Norway

27.11.2014

EU/1/09/584

Sildenafil Teva

Liechtenstein

31.10.2014

EU/1/09/584

Sildenafil Teva

Iceland

23.9.2014

EU/1/09/584

Sildenafil Teva

Norway

2.10.2014

EU/1/09/585

Rivastigmine 1A Pharma

Iceland

9.9.2014

EU/1/09/585

Rivastigmine 1A Pharma

Norway

10.9.2014

EU/1/09/586

Oslif Breezhaler

Liechtenstein

31.10.2014

EU/1/09/586

Oslif Breezhaler

Iceland

25.9.2014

EU/1/09/586

Oslif Breezhaler

Norway

14.10.2014

EU/1/09/587

Olanzapine Glenmark

Liechtenstein

31.8.2014

EU/1/09/587

Olanzapine Glenmark

Iceland

9.9.2014

EU/1/09/587

Olanzapine Glenmark

Norway

10.9.2014

EU/1/09/588

Olanzapine Glenmark Europe

Liechtenstein

31.8.2014

EU/1/09/588

Olanzapine Glenmark Europe

Iceland

9.9.2014

EU/1/09/588

Olanzapine Glenmark Europe

Norway

10.9.2014

EU/1/09/589

Rivastigmine HEXAL

Liechtenstein

31.8.2014

EU/1/09/589

Rivastigmine HEXAL

Iceland

13.8.2014

EU/1/09/589

Rivastigmine Hexal

Norway

13.8.2014

EU/1/09/590

Prevenar 13

Liechtenstein

31.12.2014

EU/1/09/590

Prevenar 13

Iceland

10.10.2014

EU/1/09/590

Prevenar 13

Norway

15.10.2014

EU/1/09/591

Multaq

Norway

29.9.2014

EU/1/09/591

Multaq

Iceland

26.9.2014

EU/1/09/592

Olazax Disperzi

Liechtenstein

31.8.2014

EU/1/09/592

Olazax Disperzi

Iceland

4.9.2014

EU/1/09/592

Olazax Disperzi

Norway

27.8.2014

EU/1/09/593

Onbrez Breezhaler

Liechtenstein

31.10.2014

EU/1/09/593

Onbrez Breezhaler

Iceland

25.9.2014

EU/1/09/593

Onbrez Breezhaler

Norway

14.10.2014

EU/1/09/594

Hirobrez Breezhaler

Norway

14.10.2014

EU/1/09/594

Hirobriz Breezhaler

Liechtenstein

31.10.2014

EU/1/09/594

Hirobriz Breezhaler

Iceland

25.9.2014

EU/1/09/595

Sildenafil Actavis

Iceland

23.9.2014

EU/1/09/595

Sildenafil Actavis

Norway

1.10.2014

EU/1/09/596

Lamivudine Teva Pharma B.V.

Liechtenstein

31.10.2014

EU/1/09/596

Lamivudine Teva Pharma B.V.

Iceland

23.9.2014

EU/1/09/596

Lamivudine Teva Pharma B.V.

Norway

9.10.2014

EU/1/09/597

Olazax

Iceland

9.9.2014

EU/1/09/597

Olazax

Norway

10.9.2014

EU/1/09/598

Nevirapine Teva

Iceland

10.9.2014

EU/1/09/598

Nevirapine Teva

Norway

9.9.2014

EU/1/09/599

Rivastigmine Sandoz

Iceland

13.8.2014

EU/1/09/599

Rivastigmine Sandoz

Norway

13.8.2014

EU/1/09/600

Zutectra

Iceland

24.9.2014

EU/1/09/600

Zutectra

Norway

15.10.2014

EU/1/09/601

Firdapse

Norway

18.12.2014

EU/1/09/602

Scintimun

Liechtenstein

31.8.2014

EU/1/09/602

Scintimun

Iceland

10.9.2014

EU/1/09/602

Scintimun

Norway

18.9.2014

EU/1/09/603

Sildenafil ratiopharm

Liechtenstein

31.10.2014

EU/1/09/603

Sildenafil ratiopharm

Iceland

23.9.2014

EU/1/09/603

Sildenafil ratiopharm

Norway

2.10.2014

EU/1/09/604

Leflunomide Winthrop

Liechtenstein

31.12.2014

EU/1/09/604

Leflunomide Winthrop

Iceland

12.12.2014

EU/1/09/604

Leflunomide Winthrop

Norway

28.11.2014

EU/1/09/605

Temomedac

Liechtenstein

31.8.2014

EU/1/09/605

Temomedac

Iceland

13.8.2014

EU/1/09/605

Temomedac

Norway

7.8.2014

EU/1/09/606

Temozolomide Teva

Liechtenstein

31.10.2014

EU/1/09/606

Temozolomide Teva

Iceland

10.9.2014

EU/1/09/606

Temozolomide Teva

Norway

12.9.2014

EU/1/09/607

Silodyx

Liechtenstein

31.10.2014

EU/1/09/607

Silodyx

Iceland

25.9.2014

EU/1/09/607

Silodyx

Norway

15.10.2014

EU/1/09/608

Urorec

Liechtenstein

31.10.2014

EU/1/09/608

Urorec

Iceland

25.9.2014

EU/1/09/608

Urorec

Norway

15.10.2014

EU/1/09/609

Elonva

Liechtenstein

31.8.2014

EU/1/09/609

Elonva

Iceland

10.9.2014

EU/1/09/609

Elonva

Norway

8.9.2014

EU/1/09/611

Docetaxel Teva

Liechtenstein

31.8.2014

EU/1/09/611

Docetaxel Teva

Iceland

12.8.2014

EU/1/09/611

Docetaxel Teva

Norway

6.8.2014

EU/1/10/614

Menveo

Liechtenstein

31.12.2014

EU/1/10/614

Menveo

Iceland

20.12.2014

EU/1/10/614

Menveo

Norway

12.12.2014

EU/1/10/616

Temozolomide HEXAL

Liechtenstein

31.12.2014

EU/1/10/616

Temozolomide Hexal

Iceland

12.12.2014

EU/1/10/616

Temozolomide Hexal

Norway

26.11.2014

EU/1/10/617

Temozolomid Sandoz

Liechtenstein

31.12.2014

EU/1/10/617

Temozolomide Sandoz

Iceland

16.12.2014

EU/1/10/617

Temozolomide Sandoz

Norway

28.11.2014

EU/1/10/619

DuoPlavin

Liechtenstein

31.12.2014

EU/1/10/619

DuoPlavin

Iceland

18.12.2014

EU/1/10/619

DuoPlavin

Norway

3.12.2014

EU/1/10/620

Ristfor

Liechtenstein

31.12.2014

EU/1/10/621

Ristaben

Liechtenstein

31.12.2014

EU/1/10/622

Tepadina

Liechtenstein

31.12.2014

EU/1/10/622

Tepadina

Iceland

10.12.2014

EU/1/10/622

Tepadina

Norway

28.11.2014

EU/1/10/623

DuoCover

Liechtenstein

31.12.2014

EU/1/10/623

DuoCover

Iceland

18.12.2014

EU/1/10/623

DuoCover

Norway

3.12.2014

EU/1/11/710

Votubia

Liechtenstein

31.8.2014

EU/1/11/710

Votubia

Iceland

12.8.2014

EU/1/11/710

Votubia

Norway

7.8.2014

EU/1/12/793

XALKORI

Liechtenstein

31.8.2014

EU/1/12/793

XALKORI

Iceland

10.9.2014

EU/1/12/793

XALKORI

Norway

5.9.2014

EU/1/12/794

ADCETRIS

Liechtenstein

31.8.2014

EU/1/12/794

ADCETRIS

Iceland

10.9.2014

EU/1/12/794

ADCETRIS

Norway

5.9.2014

EU/1/13/848

Erivedge

Liechtenstein

31.8.2014

EU/1/13/848

Erivedge

Iceland

17.7.2014

EU/1/13/848

Erivedge

Norway

5.8.2014

EU/1/97/044

Tasmar

Liechtenstein

31.8.2014

EU/1/97/044

Tasmar

Iceland

13.8.2014

EU/1/97/044

Tasmar

Norway

13.8.2014

EU/1/99/114

Zeffix

Iceland

18.7.2014

EU/1/99/114

Zeffix

Norway

9.7.2014

EU/1/99/123

Renagel

Liechtenstein

31.12.2014

EU/1/99/123

Renagel

Iceland

17.12.2014

EU/1/99/123

Renagel

Norway

10.12.2014

EU/2/04/043

Equilis StrepE

Norway

10.7.2014

EU/2/04/044

Aivlosin

Liechtenstein

31.10.2014

EU/2/04/044

Aivlosin

Iceland

24.9.2014

EU/2/04/044

Aivlosin

Norway

11.11.2014

EU/2/08/086

Equip WNV

Norway

12.11.2014

EU/2/08/087

Masivet

Norway

11.11.2014

EU/2/09/094

BTVPUR AlSap 8

Norway

21.7.2014

EU/2/09/095

Improvac

Norway

11.11.2014

EU/2/09/096

Leucogen

Norway

9.10.2014

EU/2/09/097

Leucofeligen FeLV/RCP

Norway

9.10.2014

EU/2/09/099

Suvaxyn PCV

Norway

21.7.2014

EU/2/09/100

Palladia

Norway

11.11.2014

EU/2/09/100

Palladia

Liechtenstein

31.8.2014

EU/2/09/100

Palladia

Iceland

15.8.2014

EU/2/09/101

Zolvix

Iceland

4.12.2014

EU/2/09/101

Zolvix

Norway

17.12.2014

EU/2/09/102

Gripovac 3

Norway

17.12.2014

EU/2/09/102

Gripovac 3

Liechtenstein

31.12.2014

EU/2/09/102

Gripovac 3

Iceland

20.12.2014

EU/2/09/103

Respiporc Flu3

Liechtenstein

31.12.2014

EU/2/09/103

RESPIPORC FLU3

Iceland

20.12.2014

EU/2/09/104

Zulvac 8 Ovis

Liechtenstein

31.12.2014

EU/2/09/104

Zulvac 8 Ovis

Iceland

4.12.2014

EU/2/09/105

Zulvac 8 Bovis

Norway

15.12.2014

EU/2/09/105

Zulvac 8 Bovis

Liechtenstein

31.12.2014

EU/2/09/105

Zulvac 8 Bovis

Iceland

4.12.2014

---

ANNEX III

List of extended marketing authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 July – 31 December 2014:

| EU Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/01/195/028-029 | Liprolog KwikPen | Norway | 20.10.2014 |
| EU/1/03/255/009-010 | Ventavis | Iceland | 14.8.2014 |
| EU/1/03/255/009-010 | Ventavis | Norway | 7.8.2014 |
| EU/1/05/320/004 | Noxafil | Iceland | 10.10.2014 |
| EU/1/05/320/004 | Noxafil | Norway | 15.10.2014 |
| EU/1/07/436/005 | Isentress | Iceland | 11.9.2014 |
| EU/1/07/436/005 | Isentress | Norway | 10.9.2014 |
| EU/1/12/753/013-017 | Signifor | Iceland | 19.12.2014 |
| EU/1/12/753/013-017 | Signifor | Norway | 3.12.2014 |
| EU/1/12/771/007-009 | Zoledronic acid Teva | Norway | 28.10.2014 |
| EU/1/12/773/013-016 | Jakavi | Iceland | 28.10.2014 |
| EU/1/12/773/013-016 | Jakavi | Norway | 15.10.2014 |
| EU/1/96/007/039-042 | Humalog KwikPen | Norway | 20.10.2014 |
| EU/1/99/117/003-004 | Synagis | Iceland | 11.9.2014 |
| EU/1/99/117/003-004 | Synagis | Norway | 11.9.2014 |
| EU/2/03/041/006-008 | Draxxin | Iceland | 12.8.2014 |
| EU/2/03/041/006-008 | Draxxin | Norway | 18.7.2014 |
| EU/2/11/135/002-003 | Panacur AquaSol | Norway | 17.12.2014 |
| EU/2/11/135/002-003 | Panacur AquaSol | Iceland | 15.8.2014 |

EU Number

Product

Country

Date of authorisation

EU/1/01/195/028-029

Liprolog KwikPen

Norway

20.10.2014

EU/1/03/255/009-010

Ventavis

Iceland

14.8.2014

EU/1/03/255/009-010

Ventavis

Norway

7.8.2014

EU/1/05/320/004

Noxafil

Iceland

10.10.2014

EU/1/05/320/004

Noxafil

Norway

15.10.2014

EU/1/07/436/005

Isentress

Iceland

11.9.2014

EU/1/07/436/005

Isentress

Norway

10.9.2014

EU/1/12/753/013-017

Signifor

Iceland

19.12.2014

EU/1/12/753/013-017

Signifor

Norway

3.12.2014

EU/1/12/771/007-009

Zoledronic acid Teva

Norway

28.10.2014

EU/1/12/773/013-016

Jakavi

Iceland

28.10.2014

EU/1/12/773/013-016

Jakavi

Norway

15.10.2014

EU/1/96/007/039-042

Humalog KwikPen

Norway

20.10.2014

EU/1/99/117/003-004

Synagis

Iceland

11.9.2014

EU/1/99/117/003-004

Synagis

Norway

11.9.2014

EU/2/03/041/006-008

Draxxin

Iceland

12.8.2014

EU/2/03/041/006-008

Draxxin

Norway

18.7.2014

EU/2/11/135/002-003

Panacur AquaSol

Norway

17.12.2014

EU/2/11/135/002-003

Panacur AquaSol

Iceland

15.8.2014

---

ANNEX IV

List of withdrawn marketing authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 July – 31 December 2014:

| EU Number | Product | Country | Date of withdrawal |
| --- | --- | --- | --- |
| EU/1/06/339 | Preotact | Iceland | 12.8.2014 |
| EU/1/06/339 | Preotact | Norway | 13.8.2014 |
| EU/1/07/426 | Olanzapine Cipla | Liechtenstein | 31.8.2014 |
| EU/1/07/426 | Olanzapine Cipla | Iceland | 22.7.2014 |
| EU/1/08/467 | Doribax | Liechtenstein | 31.8.2014 |
| EU/1/08/467 | Doribax | Iceland | 15.8.2014 |
| EU/1/08/467 | Doribax | Norway | 13.8.2014 |
| EU/1/09/557 | Clopidogrel Qualimed | Liechtenstein | 31.10.2014 |
| EU/1/09/557 | Clopidogrel Qualimed | Iceland | 10.9.2014 |
| EU/1/09/557 | Clopidogrel Qualimed | Norway | 14.10.2014 |
| EU/1/10/649 | Clopidogrel Teva Pharma B.V. | Liechtenstein | 31.10.2014 |
| EU/1/10/649 | Clopidogrel Teva Pharma B.V. | Iceland | 19.11.2014 |
| EU/1/10/661 | FLUENZ | Liechtenstein | 31.12.2014 |
| EU/1/10/661 | Fluenz | Iceland | 18.11.2014 |
| EU/1/10/661 | Fluenz | Norway | 17.12.2014 |
| EU/1/10/662 | Docetaxel Teva Pharma | Iceland | 12.8.2014 |
| EU/1/11/675 | Leflunomide Teva | Iceland | 12.8.2014 |
| EU/1/11/689 | IOA | Liechtenstein | 31.8.2014 |
| EU/1/11/689 | Ioa | Iceland | 2.9.2014 |
| EU/1/11/689 | IOA | Norway | 16.9.2014 |
| EU/1/11/723 | Pioglitazon Krka | Liechtenstein | 31.10.2014 |
| EU/1/11/723 | Pioglitazone Krka | Iceland | 24.9.2014 |
| EU/1/11/735 | Ipreziv | Liechtenstein | 31.12.2014 |
| EU/1/11/735 | Ipreziv | Iceland | 19.11.2014 |
| EU/1/11/735 | Ipreziv | Norway | 17.12.2014 |
| EU/1/11/744 | Topotecan Eagle | Liechtenstein | 31.10.2014 |
| EU/1/11/744 | Topotecan Eagle | Iceland | 27.10.2014 |
| EU/1/11/744 | Topotecan Eagle | Norway | 5.11.2014 |
| EU/1/14/911 | Rivastigmine 3M Health Care Ltd. | Liechtenstein | 31.8.2014 |
| EU/1/14/911 | Rivastigmine 3M Health Care Ltd. | Iceland | 4.9.2014 |
| EU/1/14/911 | Rivastigmine 3M Health Care Ltd. | Norway | 16.9.2014 |
| EU/1/97/037 | Vistide | Liechtenstein | 31.10.2014 |
| EU/1/97/037 | Vistide | Iceland | 10.9.2014 |
| EU/1/97/043 | Revasc | Liechtenstein | 31.8.2014 |
| EU/1/97/043 | Revasc | Iceland | 14.8.2014 |
| EU/1/97/043 | Revasc | Norway | 26.8.2014 |
| EU/2/06/058 | Flexicam | Iceland | 12.8.2014 |

EU Number

Product

Country

Date of withdrawal

EU/1/06/339

Preotact

Iceland

12.8.2014

EU/1/06/339

Preotact

Norway

13.8.2014

EU/1/07/426

Olanzapine Cipla

Liechtenstein

31.8.2014

EU/1/07/426

Olanzapine Cipla

Iceland

22.7.2014

EU/1/08/467

Doribax

Liechtenstein

31.8.2014

EU/1/08/467

Doribax

Iceland

15.8.2014

EU/1/08/467

Doribax

Norway

13.8.2014

EU/1/09/557

Clopidogrel Qualimed

Liechtenstein

31.10.2014

EU/1/09/557

Clopidogrel Qualimed

Iceland

10.9.2014

EU/1/09/557

Clopidogrel Qualimed

Norway

14.10.2014

EU/1/10/649

Clopidogrel Teva Pharma B.V.

Liechtenstein

31.10.2014

EU/1/10/649

Clopidogrel Teva Pharma B.V.

Iceland

19.11.2014

EU/1/10/661

FLUENZ

Liechtenstein

31.12.2014

EU/1/10/661

Fluenz

Iceland

18.11.2014

EU/1/10/661

Fluenz

Norway

17.12.2014

EU/1/10/662

Docetaxel Teva Pharma

Iceland

12.8.2014

EU/1/11/675

Leflunomide Teva

Iceland

12.8.2014

EU/1/11/689

IOA

Liechtenstein

31.8.2014

EU/1/11/689

Ioa

Iceland

2.9.2014

EU/1/11/689

IOA

Norway

16.9.2014

EU/1/11/723

Pioglitazon Krka

Liechtenstein

31.10.2014

EU/1/11/723

Pioglitazone Krka

Iceland

24.9.2014

EU/1/11/735

Ipreziv

Liechtenstein

31.12.2014

EU/1/11/735

Ipreziv

Iceland

19.11.2014

EU/1/11/735

Ipreziv

Norway

17.12.2014

EU/1/11/744

Topotecan Eagle

Liechtenstein

31.10.2014

EU/1/11/744

Topotecan Eagle

Iceland

27.10.2014

EU/1/11/744

Topotecan Eagle

Norway

5.11.2014

EU/1/14/911

Rivastigmine 3M Health Care Ltd.

Liechtenstein

31.8.2014

EU/1/14/911

Rivastigmine 3M Health Care Ltd.

Iceland

4.9.2014

EU/1/14/911

Rivastigmine 3M Health Care Ltd.

Norway

16.9.2014

EU/1/97/037

Vistide

Liechtenstein

31.10.2014

EU/1/97/037

Vistide

Iceland

10.9.2014

EU/1/97/043

Revasc

Liechtenstein

31.8.2014

EU/1/97/043

Revasc

Iceland

14.8.2014

EU/1/97/043

Revasc

Norway

26.8.2014

EU/2/06/058

Flexicam

Iceland

12.8.2014

---

ANNEX V

List of suspended marketing authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 July – 31 December 2014:

| EU Number | Product | Country | Date of suspension |
| --- | --- | --- | --- |
| EU/1/13/847 | MACI | Liechtenstein | 31.12.2014 |
| EU/1/13/847 | MACI | Iceland | 19.12.2014 |

EU Number

Product

Country

Date of suspension

EU/1/13/847

MACI

Liechtenstein

31.12.2014

EU/1/13/847

MACI

Iceland

19.12.2014

---